- Market Capitalization, $K 113,963,400
- Shares Outstanding, K 2,504,140
- Annual Sales, $ 42,147 M
- Annual Income, $ 3,256 M
- 60-Month Beta 0.51
- Price/Sales 2.89
- Price/Cash Flow 6.94
- Price/Book 1.65
|Period||Period Low||Period High||Performance|
| || |
-4.87 (-9.71%)since 09/30/20
| || |
-7.20 (-13.71%)since 07/30/20
| || |
-2.16 (-4.55%)since 10/30/19
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.
Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.
During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
CAMBRIDGE, Mass. and NEW YORK and , /PRNewswire/ -- Sanofi and the Parkinson's Foundation today announced a new research collaboration to advance the availability of genetic testing and counseling...
The Zacks Analyst Blog Highlights: Amazon, Home Depot, Sanofi, Intel and AMT
Top Stock Reports for Amazon, Home Depot & Sanofi
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
SNY vs. NVO: Which Stock Is the Better Value Option?
|Value Line Dividend Idx ETF FT|
|France Ishares MSCI ETF|
|Pharmaceutical Vaneck ETF|
|Ishares Genomics Immunology and Healthcare ETF|
|Intl Value Factor Ishares Edge MSCI ETF|